Fast-Track:Biomagnetic In-vivo Imaging of Ovarian Cancer

快速通道：卵巢癌生物磁体内成像

• 批准号: 7386095
• 负责人: EDWARD R FLYNN
• 金额: $ 20.84万
• 依托单位: SENIOR SCIENTIFIC
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7386095
• 关键词: Antibodies; Antineoplastic Agents; Austria; Biochemical; Biological; Biology; Biopsy; CA-125 Antigen; Cancer cell line; Cancerous; Cell Count; Cell Line; Cells; Cessation of life; Characteristics; Clinical; Clinical Trials; Clinical trial protocol document; Complement; Contrast Media; Count; Cytometry; Data; Depth; Detection; Development; Disease; Disorder by Site; Early Diagnosis; Frequencies; Goals; Graft Rejection; Histology; Human; Human body; Image; In Vitro; Individual; Injection of therapeutic agent; International; Investigation; Iron; Label; Lead; Lesion; Life; Lipids; Localized; Location; Magnetic Resonance Imaging; Magnetism; Malignant Neoplasms; Malignant neoplasm of ovary; Measurement; Measures; Medicine; Methodology; Methods; Modeling; Monitor; Nanotechnology; Noise; Numbers; Object Attachment; Organ; Ovarian; Ovarian Tissue; Ovary; Patients; Personal Satisfaction; Pharmaceutical Preparations; Phase; Physics; Physiologic pulse; Placement; Positioning Attribute; Premalignant; Procedures; Property; Publishing; Pulse taking; Radiation; Range; Research; Sampling; Screening for Ovarian Cancer; Sensitivity and Specificity; Serum; Signal Transduction; Site; Source; Spatial Distribution; Structure; System; Techniques; Tissue Extracts; Ultrasonography; Urine; Woman; angiogenesis; cancer cell; cancer site; cancer therapy; cancer type; chemotherapy; clinical application; design; follow-up; human subject; human tissue; improved; in vivo; magnetic field; malignant breast neoplasm; mouse model; nanobiotechnology; nanoparticle; novel; ovarian neoplasm; particle; programs; research study; response; sensor; size; small molecule; success; superconducting quantum interference device; symposium; targeted delivery; theories; tumor

DESCRIPTION (provided by applicant): A novel method for applying nanotechnology to the early detection, localization and potential treatment of ovarian cancer has been developed. Recent measurements, using live ovarian cancer cell lines and the ovarian cancer marker CA-125, have shown that the sensitivity of this method is better than 105 cells at depths of 5 - 8 cm from the sensor. This is significantly more sensitive than the 108 cells required for ultrasound or x-ray imaging. Sensitive biomagnetic sensors are used to measure the remanence fields of superparamagnetic nanoparticles conjugated with specific markers for ovarian cancer cells or pre-cancerous lesions. Measurements indicate that 104 nanoparticles attach to each cancer cell yielding a high magnetic moment/cell. An array of SQUID sensors are used to detect and localize these superparamagnetic nanoparticles. In order to develop protocols for clinical trials, experiments are proposed using nanoparticles, labeled with several ovarian markers, injected into phantom ovaries, ovarian tissue, and extracted human ovaries. Following this, multicomponent nanoparticles, containing both marker and anti-cancer molecules will be investigated for cancer destruction using magnetic concentration. In subsequent clinical applications, labeled-magnetic nanoparticles will be injected into the patient using the procedures developed in these studies.

描述（申请人提供）：一种将纳米技术应用于卵巢癌的早期检测、定位和潜在治疗的新方法已经被开发出来。最近使用活卵巢癌细胞系和卵巢癌标记物CA-125进行的测量表明，该方法的灵敏度优于距离传感器5 - 8厘米深度的105个细胞。这比超声波或x射线成像所需的108个细胞要灵敏得多。灵敏的生物磁传感器用于测量与卵巢癌细胞或癌前病变特异性标志物结合的超顺磁性纳米颗粒的剩余场。测量表明，104个纳米粒子附着在每个癌细胞上，每个细胞产生高磁矩。一组SQUID传感器被用来检测和定位这些超顺磁性纳米颗粒。为了制定临床试验方案，实验建议使用纳米颗粒，标记几种卵巢标志物，注射到幻卵巢、卵巢组织和提取的人类卵巢中。在此基础上，将研究同时含有标记分子和抗癌分子的多组分纳米颗粒，利用磁浓缩法破坏癌症。在随后的临床应用中，将使用这些研究中开发的程序将标记磁性纳米颗粒注射到患者体内。